AGL 38.40 Increased By ▲ 0.25 (0.66%)
AIRLINK 128.80 Increased By ▲ 3.73 (2.98%)
BOP 7.30 Increased By ▲ 0.45 (6.57%)
CNERGY 4.56 Increased By ▲ 0.11 (2.47%)
DCL 8.29 Increased By ▲ 0.38 (4.8%)
DFML 38.65 Increased By ▲ 1.31 (3.51%)
DGKC 80.00 Increased By ▲ 2.23 (2.87%)
FCCL 31.99 Increased By ▲ 1.41 (4.61%)
FFBL 72.85 Increased By ▲ 3.99 (5.79%)
FFL 12.29 Increased By ▲ 0.43 (3.63%)
HUBC 110.20 Increased By ▲ 5.70 (5.45%)
HUMNL 14.03 Increased By ▲ 0.54 (4%)
KEL 5.01 Increased By ▲ 0.36 (7.74%)
KOSM 7.49 Increased By ▲ 0.32 (4.46%)
MLCF 38.00 Increased By ▲ 1.56 (4.28%)
NBP 71.23 Increased By ▲ 5.31 (8.06%)
OGDC 188.30 Increased By ▲ 8.77 (4.88%)
PAEL 25.20 Increased By ▲ 0.77 (3.15%)
PIBTL 7.30 Increased By ▲ 0.15 (2.1%)
PPL 151.70 Increased By ▲ 8.00 (5.57%)
PRL 25.14 Increased By ▲ 0.82 (3.37%)
PTC 17.35 Increased By ▲ 0.95 (5.79%)
SEARL 81.95 Increased By ▲ 3.38 (4.3%)
TELE 7.49 Increased By ▲ 0.27 (3.74%)
TOMCL 32.85 Increased By ▲ 0.88 (2.75%)
TPLP 8.48 Increased By ▲ 0.35 (4.31%)
TREET 16.60 Increased By ▲ 0.47 (2.91%)
TRG 56.54 Increased By ▲ 1.88 (3.44%)
UNITY 27.97 Increased By ▲ 0.47 (1.71%)
WTL 1.36 Increased By ▲ 0.07 (5.43%)
BR100 10,473 Increased By 383.7 (3.8%)
BR30 30,953 Increased By 1443.9 (4.89%)
KSE100 97,935 Increased By 3361.3 (3.55%)
KSE30 30,551 Increased By 1106.1 (3.76%)

Playing tailor-made video games can help children with attention deficit hyperactivity disorder (ADHD), according to results from a pivotal clinical trial announced on Monday. The US company developing the treatment, unlisted Akili, now plans to file for regulatory approval with the US Food and Drug Administration in the first half of 2018, paving the way for what would be the first such "digital" prescription product. Akili is an affiliate of London-listed PureTech Health.
Cases of ADHD have been rising around the world in recent decades, with children often given drugs to treat the disorder. Akili's product takes a different approach by using a game to stimulate specific cognitive neural systems in the brain. In the randomised, controlled trial of 348 children and adolescents with ADHD, Akili's product AKL-T01 showed a statistically significant improvement compared with an active control in attention performance. The control was also a video game.
Medicating ADHD is big business, with Shire a leading player in the field. Shire is also an investor in Akili.

Comments

Comments are closed.